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moderately obese subjects in our study was iden-
tical to that reported in a recent meta-analysis 
on long-term pharmacotherapy for obesity.2
In response to Ornish’s letter: the low-carbo-
hydrate diet was based on Atkins’s book, although 
we encouraged the study participants to consume 
a variety of protein and fat sources to maintain 
successful long-term adherence. We specifically 
reported on retention in detail and noted that ad-
herence was higher in this trial than in any other 
trial of a similar length that we know of. The set-
ting and methods we used to maximize adherence 
rates permitted a robust test of the three dietary 
strategies, as assessed by weight loss and estab-
lished measurements of lipids, glycemic control, 
and hepatic and inflammatory biomarkers. As 
noted by Manzoni and colleagues, we did not as-
sess cost-effectiveness. However, we believe that 
cost-effective interventions can be implemented 
in the workplace, with the use of group meetings 
and by working with food-service providers.
Several readers have informed us that our on-
line Supplementary Appendix was incomplete. We 
have updated the appendix to provide more com-
plete information.
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Tibolone in Older Postmenopausal Women
To the Editor: In a randomized study of the ef-
fect of tibolone on fracture rates among post-
menopausal women between the ages of 60 and 
85 years, Cummings et al. (Aug. 14 issue)1 report 
that tibolone significantly reduced the risk of in-
vasive breast cancer. The authors also report that 
this finding contradicted the results of the ob-
servational Million Women Study, which showed 
that the use of tibolone for up to 5 years was as-
sociated with an increased risk of breast cancer.2 
In analyses combining clinical-trial and observa-
tional-study cohorts, the Women’s Health Initiative 
(WHI) showed that a decreased risk of breast can-
cer was associated with estrogen therapy only if 
estrogen was given several years after menopause 
and not when it was begun soon thereafter.3 
Since women in nontrial settings usually begin 
such hormonal therapy shortly after the onset of 
menopause, the gap time after menopause pro-
vides a potential effect modifier, suggesting cau-
tion in extrapolating findings to women closer to 
menopause. In the WHI randomized trial, estro-
gen plus progestin increased the risk of breast 
cancer that was diagnosed at an advanced stage, 
suggesting diagnostic delay with fewer cancers in 
the hormone group through the first 3 years of 
follow-up.4 The current tibolone trial was report-
ed after a median of 34 months and without 
information on tumor stage. Although tibolone 
does not increase breast density, as does com-
bined hormone therapy,5 could diagnostic delay 
account for some of the breast-cancer findings?
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To the Editor: With respect to the study by 
Cummings et al, we raise two issues: First, among 
the risk factors for stroke, the authors did not in-
clude the presence of high triglyceride levels and 
low levels of high-density lipoprotein (HDL) cho-
lesterol, which have been shown to be related to 
ischemic cerebrovascular events.1,2 Were these val-
ues similar in the two study groups at baseline? 
Were they modified by the administration of ti-
bolone?
Second, regarding gynecologic outcomes, pa-
tients who were treated with tibolone had a sig-
nificantly higher incidence of mild cervical dyspla-
sia on cytologic analysis than did those receiving 
placebo (7.6% vs. 3.2%, P = 0.009), but there were 
no differences between the groups in the incidence 
of moderate-to-severe dysplasia. Several studies 
have noted a synergistic role of sex hormones with 
human papillomavirus (HPV) infection in facili-
tating cervical carcinogenesis by inducing squa-
mous metaplasia and by modifying the local im-
mune microenvironment.3,4 This carcinogenic 
process requires several years. In the study by 
Cummings et al., the median duration of treat-
ment was 34 months. We wonder whether in this 
period of time the possible HPV hyperactivation 
induced by tibolone could have caused mild dys-
plasia, whereas higher-grade dysplasia would have 
required a longer exposure.
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The authors reply: Chlebowski and Prentice 
wonder whether a delay in diagnosis might ac-
count for some of the reduction in the risk of 
breast cancer that we observed among patients 
receiving tibolone. There was no significant dif-
ference between the groups in the use of mam-
mography. As Chlebowski and Prentice note, ti-
bolone does not appear to increase breast density, 
and there is no other reason why tumors would 
be more difficult to detect in women taking tibo-
lone. Although data about the stage of cancers at 
diagnosis were not available in the trial, it seems 
unlikely that diagnostic delay could account for a 
meaningful part of the 68% decreased risk of 
invasive breast cancer.
Serati and colleagues ask whether changes in 
cholesterol and triglycerides might account for 
the increased risk of stroke we observed in pa-
tients receiving tibolone. We did not measure 
lipid concentrations in our trial, precluding an 
analysis of how much of the increased risk of 
stroke might have been due to changes in lipids. 
However, in previous placebo-controlled trials,1 
2 years of treatment with 1.25 mg or 2.5 mg of 
tibolone daily resulted in decreases in HDL cho-
lesterol levels of 14% and 22%, decreases in 
triglyceride levels of 21% and 23%, and decreas-
es in lipoprotein(a) levels of 40% and 51%, re-
spectively, whereas there were no significant 
changes in levels of low-density lipoprotein cho-
lesterol (an increase of 3% and a decrease of 2%, 
respectively). We have no data from our trial and 
know of no other studies that address the specu-
lation raised by Serati et al. as to whether tibo-
lone might activate HPV.
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